Kidney Cancer

A recent study found that patients with metastatic renal cell carcinoma may see extended response even after stopping immunotherapy treatment.

Patients with metastatic kidney cancer may see a decreased efficacy of their immunotherapy regimen if they recently took antibiotics.

Sutent treatment breaks seem to have no effect on clinical efficacy for patients with renal cell carcinoma.

CURE spoke with Neeraj Agarwal, M.D., about the underreporting and underemphasizing of toxicities with PD-1 inhibitors in renal cell carcinoma.

Vaccines are currently being tested in their potential to improve immunotherapy responses for patients with renal cell carcinoma.

Elizabeth Plimack, M.D., discusses an update on the CheckMate-025 trial, comparing Opdivo to Afinitor in patients with metastatic renal cell carcinoma.

David F. McDermott, M.D., is optimistic about combination regimens shaping the treatment landscape for renal cell carcinoma.

After the approvals of agents in the second-line setting, researchers are now turning to improving the frontline treatment of kidney cancer.

Will the newly approved kidney cancer treatments eventually end up in the frontline setting? Expert Chung-Han (Joe) Lee, M.D., weighs in.

Obesity can negatively affect cancer treatment outcomes, trigger disease recurrence and shorten longevity. Organized weight loss programs and exercise can help patients protect themselves.

Immunotherapy combinations are on the horizon for the treatment of renal cell carcinoma, Robert J. Motzer, M.D., says.

Melanoma should not be considered to be in a "special category" that responds well to immunotherapy, according to Christian M. Capitini, M.D., assistant professor of Pediatrics at the University of Wisconsin.

A panel of experts recently discussed the evolving field of immunotherapy for solid tumor types.

TKIs will continue to shape the landscape of kidney cancer treatment, Robert A. Figlin, M.D., F.A.C.P., says.

Cabometyx was proved to be superior to Sutent, reducing rates of disease progression or death for patients with metastatic RCC, according to a recent trial.

In a recent phase 2 trial, Cabometyx showed longer progression-free survival than Sutent in patients with metastatic kidney cancer.

After going through the "Dark Ages," we're approaching the "Golden Age" of kidney cancer care, with more options available than ever, says James Hsieh.

There have been some exciting advances in using immunotherapy to treat GU malignancies such as kidney and bladder cancer. CURE sat down with Elizabeth Plimack, M.D. to discuss them.

The treatment landscape for advanced kidney cancer has changed dramatically over the past few years, with several targeted drugs and an immunotherapy approved by the FDA.

Ten years ago, patients with advanced RCC had very few treatment options, yet today, there are multiple therapeutic strategies and more in the pipeline for this not-very-common tumor type, writes our editor-in-chief, Debu Tripathy.

While many new treatment options have been introduced for kidney cancer in recent years, the question of how to sequence them is still being debated.

A recent study showed a correlation between higher body mass index and survival in some patients with kidney cancer.

Most people don't know much about kidney cancer at the time of their diagnosis. The Kidney Cancer Association wants to change that.

Jorge Garcia offers insight about the benefits of Cabometyx and the drug's impact on RCC.

Randy F. Sweis talks to CURE about the future of treatment for GU cancers.

A recent phase 3 study showed that Sutent extended disease-free survival for patients with renal cell carcinoma.

Sumanta K. Pal weighs in on a new drug combination that is showing promise for patients with RCC who progressed on Cabometyx (cabozantinib) and Opdivo (nivolumab).

The treatment paradigm in renal cell carcinoma (RCC) has expanded over recent months to include three practice-changing agents in the second-line setting.

Not only is Opdivo changing the way RCC is being treated, but the immunotherapy is also here to stay, according to David F. McDermott.